oprelvekin

Home
Ligands
oprelvekin

GtoPdb Ligand ID: 6971

Synonyms: Neumega®

oprelvekin is an approved drug (FDA (1997))

Compound class: Peptide or derivative

Comment: This is a non-glycosylated, recombinant form of human IL-11 produced in E.coli. Oprelvekin is one amino acid shorter than the endogenous peptide, lacking the amino-terminal proline residue.

References
1. Berl T, Schwertschlag U. (2000) Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent. Oncology (Williston Park, NY), 14 (9 Suppl 8): 12-20. [PMID:11033834]
2. Jung Y, Ahn H, Kim DS, Hwang YR, Ho SH, Kim JM, Kim S, Ma S, Kim S. (2011) Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis. Biochem Biophys Res Commun, 405 (3): 399-404. [PMID:21238428]
3. Wilde MI, Faulds D. (1998) Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs, 10 (2): 159-71. [PMID:18020592]

References

1. Berl T, Schwertschlag U. (2000)
Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent.
Oncology (Williston Park, NY), 14 (9 Suppl 8): 12-20. [PMID:11033834]

2. Jung Y, Ahn H, Kim DS, Hwang YR, Ho SH, Kim JM, Kim S, Ma S, Kim S. (2011)
Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis.
Biochem Biophys Res Commun, 405 (3): 399-404. [PMID:21238428]

3. Wilde MI, Faulds D. (1998)
Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.
BioDrugs, 10 (2): 159-71. [PMID:18020592]